830 related articles for article (PubMed ID: 31221620)
1. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
[TBL] [Abstract][Full Text] [Related]
2. Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.
Saadatmand S; Rutgers EJ; Tollenaar RA; Zonderland HM; Ausems MG; Keymeulen KB; Schlooz-Vries MS; Koppert LB; Heijnsdijk EA; Seynaeve C; Verhoef C; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MM
BMC Cancer; 2012 Oct; 12():440. PubMed ID: 23031619
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
4. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
[TBL] [Abstract][Full Text] [Related]
5. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
6. One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study.
Zackrisson S; Lång K; Rosso A; Johnson K; Dustler M; Förnvik D; Förnvik H; Sartor H; Timberg P; Tingberg A; Andersson I
Lancet Oncol; 2018 Nov; 19(11):1493-1503. PubMed ID: 30322817
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
8. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study.
Lång K; Josefsson V; Larsson AM; Larsson S; Högberg C; Sartor H; Hofvind S; Andersson I; Rosso A
Lancet Oncol; 2023 Aug; 24(8):936-944. PubMed ID: 37541274
[TBL] [Abstract][Full Text] [Related]
9. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
[TBL] [Abstract][Full Text] [Related]
10. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial.
Heindel W; Weigel S; Gerß J; Hense HW; Sommer A; Krischke M; Kerschke L;
Lancet Oncol; 2022 May; 23(5):601-611. PubMed ID: 35427470
[TBL] [Abstract][Full Text] [Related]
11. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
[TBL] [Abstract][Full Text] [Related]
12. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
13. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.
Kuhl C; Weigel S; Schrading S; Arand B; Bieling H; König R; Tombach B; Leutner C; Rieber-Brambs A; Nordhoff D; Heindel W; Reiser M; Schild HH
J Clin Oncol; 2010 Mar; 28(9):1450-7. PubMed ID: 20177029
[TBL] [Abstract][Full Text] [Related]
14. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in
Guindalini RSC; Zheng Y; Abe H; Whitaker K; Yoshimatsu TF; Walsh T; Schacht D; Kulkarni K; Sheth D; Verp MS; Bradbury AR; Churpek J; Obeid E; Mueller J; Khramtsova G; Liu F; Raoul A; Cao H; Romero IL; Hong S; Livingston R; Jaskowiak N; Wang X; Debiasi M; Pritchard CC; King MC; Karczmar G; Newstead GM; Huo D; Olopade OI
Clin Cancer Res; 2019 Mar; 25(6):1786-1794. PubMed ID: 30154229
[TBL] [Abstract][Full Text] [Related]
15. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
Kriege M; Brekelmans CT; Boetes C; Muller SH; Zonderland HM; Obdeijn IM; Manoliu RA; Kok T; Rutgers EJ; de Koning HJ; Klijn JG;
Cancer; 2006 Jun; 106(11):2318-26. PubMed ID: 16615112
[TBL] [Abstract][Full Text] [Related]
16. Tumour characteristics of bilateral screen-detected cancers and bilateral interval cancers in women participating at biennial screening mammography.
van Bommel R; Lameijer JRC; Voogd AC; Nederend J; Louwman MWJ; Setz-Pels W; Strobbe LJ; Tjan-Heijnen VCG; Duijm LE
Eur J Radiol; 2018 Nov; 108():215-221. PubMed ID: 30396659
[TBL] [Abstract][Full Text] [Related]
17. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
[TBL] [Abstract][Full Text] [Related]
18. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Saadatmand S; Obdeijn IM; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Woldringh GH; Bergers E; Verhoef C; Heijnsdijk EA; Hooning MJ; de Koning HJ; Tilanus-Linthorst MM
Int J Cancer; 2015 Oct; 137(7):1729-38. PubMed ID: 25820931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
